Traitement en cours

Veuillez attendre...

Paramétrages

Paramétrages

Aller à Demande

1. WO2019109150 - PROCÉDÉS DE TRAITEMENT DE L'AGITATION

Note: Texte fondé sur des processus automatiques de reconnaissance optique de caractères. Seule la version PDF a une valeur juridique

[ EN ]

THE CLAIMS DEFINING THE INVENTION ARE AS FOLLOWS:

1. A method of treating agitation associated with neurodegenerative disorders in a patient in need thereof, the method including the step of administering an effective amount of a compound of formula (I) or pharmaceutically acceptable salt thereof:


2. Use of a compound of formula (I), or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating agitation associated with neurodegenerative disorders in a patient in need thereof.

3. Use of a compound of formula (I), or a pharmaceutically acceptable salt thereof, for treating agitation associated with neurodegenerative disorders in a patient in need thereof.

4. A method or use according to any one of claims 1 to 3 wherein the treatment step is conducted in the absence of adjunct antidepressant therapy.

5. A method or use according to any one of claims 1 to 4 wherein the

neurodegenerative disorder is dementia, for instance, Lewy Body Dementia.

6. A method or use according to any one of claims 1 to 4 wherein the agitation is in an elderly patient.

7. A method or use according to any one of claims 1 to 3 wherein the

neurodegenerative disorder is Huntington's disease.

8. A method or use according to any one of claims 1 to 3 wherein the

neurodegenerative disorder is multiple sclerosis.

9. A method or use according to any one of claim 8 wherein the multiple sclerosis is in a non-eldrely patient.

10. A method or use according to any one of claims 1 to 9 wherein the patient doesn’t suffer from an anxiety disorder.

11. A method or use according to any one of claims 1 to 10 wherein the compound of formula (I) is taken in combination with neurodegenerative treatments.

12. A method or use according to claim 11 wherein the neurodegenerative treatment is selected from one or more of the following: acetylcholinesterase inhibitor treatment (e.g., Aricept, Exelon) and treatments for multiple sclerosis (e.g., Avonex,

Betaseron, Copaxone, Tysabri, Gilenya).